{"groups":[{"description":"Participants who were randomized to receive quizartinib treatment regimen.","id":"FG000","title":"Quizartinib"},{"description":"Participants who were randomized to receive placebo treatment regimen.","id":"FG001","title":"Placebo"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"41"},{"groupId":"FG001","numSubjects":"70"}],"type":"Refractory disease"},{"reasons":[{"groupId":"FG000","numSubjects":"44"},{"groupId":"FG001","numSubjects":"65"}],"type":"Relapse"},{"reasons":[{"groupId":"FG000","numSubjects":"58"},{"groupId":"FG001","numSubjects":"23"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"25"},{"groupId":"FG001","numSubjects":"23"}],"type":"Subject decision to stop study drug"},{"reasons":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"11"}],"type":"Other reasons not specified"},{"reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"6"}],"type":"Non-protocol-specified AML therapy"},{"reasons":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"7"}],"type":"Investigator decision"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"12"}],"type":"Failure to meet continuation criteria"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Pregnancy"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Death"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"268"},{"groupId":"FG001","numSubjects":"271"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"265"},{"groupId":"FG001","numSubjects":"268"}],"type":"Safety Analysis Set"},{"achievements":[{"groupId":"FG000","numSubjects":"56"},{"groupId":"FG001","numSubjects":"52"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"212"},{"groupId":"FG001","numSubjects":"219"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"A total of 539 participants who met all inclusion criteria and no exclusion criteria were randomized to treatment at 193 study sites in the following countries: Spain, Italy, Republic of Korea, Japan, China, US, France, Brazil, Germany, Russian Federation, Taiwan, Hungary, Czech Republic, Romania, Israel, Canada, Serbia, Poland, Portugal, Australia, Belgium, Bulgaria, Croatia, Ukraine, Singapore, and the UK. A total of 6 participants were randomized, but did not received treatment."}